CA2321199A1 - Compositions and methods for regulating lymphocyte activation - Google Patents

Compositions and methods for regulating lymphocyte activation Download PDF

Info

Publication number
CA2321199A1
CA2321199A1 CA002321199A CA2321199A CA2321199A1 CA 2321199 A1 CA2321199 A1 CA 2321199A1 CA 002321199 A CA002321199 A CA 002321199A CA 2321199 A CA2321199 A CA 2321199A CA 2321199 A1 CA2321199 A1 CA 2321199A1
Authority
CA
Canada
Prior art keywords
val
pro
ser
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002321199A
Other languages
English (en)
French (fr)
Inventor
William A. Brady
Martha Hayden Ledbetter
Jeffrey A. Ledbetter
Raj Dua
Che-Leung Law
Laura S. Grosmaire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xcyte Therapies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2321199A1 publication Critical patent/CA2321199A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002321199A 1998-02-19 1999-02-18 Compositions and methods for regulating lymphocyte activation Abandoned CA2321199A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7527498P 1998-02-19 1998-02-19
US60/075,274 1998-02-19
US10868398P 1998-11-16 1998-11-16
US60/108,683 1998-11-16
PCT/US1999/003309 WO1999042077A2 (en) 1998-02-19 1999-02-18 Compositions and methods for regulating lymphocyte activation

Publications (1)

Publication Number Publication Date
CA2321199A1 true CA2321199A1 (en) 1999-08-26

Family

ID=26756645

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002321199A Abandoned CA2321199A1 (en) 1998-02-19 1999-02-18 Compositions and methods for regulating lymphocyte activation

Country Status (14)

Country Link
US (3) US20020155604A1 (xx)
EP (1) EP1469883A2 (xx)
JP (1) JP2003525016A (xx)
KR (1) KR20010034512A (xx)
CN (1) CN1316910A (xx)
AU (1) AU3295299A (xx)
BR (1) BR9907950A (xx)
CA (1) CA2321199A1 (xx)
HK (1) HK1041210A1 (xx)
ID (1) ID26964A (xx)
IL (1) IL137963A0 (xx)
NO (1) NO20004095L (xx)
NZ (1) NZ506453A (xx)
WO (1) WO1999042077A2 (xx)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1176981T3 (da) 1999-05-07 2006-04-10 Genentech Inc Behandling af autoimmune sygdomme med antagonister som binder til B celleoverflademarkörer
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
US7943129B2 (en) * 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US20040053340A1 (en) * 2000-12-13 2004-03-18 De Haard Johannes Joseph Protein arrays
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US8163289B2 (en) 2001-03-09 2012-04-24 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
WO2002072608A2 (en) 2001-03-09 2002-09-19 University Of Chicago POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS
GB0110029D0 (en) * 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
JP4213586B2 (ja) * 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
ATE423571T1 (de) 2001-10-12 2009-03-15 Schering Corp Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten
JP2005289809A (ja) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US20090217404A1 (en) * 2002-09-27 2009-08-27 Lowe Scott W Cell-based RNA interference and related methods and compositions
US20090186839A1 (en) * 2003-02-17 2009-07-23 Cold Spring Harbor Laboratory Model for studying the role of genes in chemoresistance
WO2004074445A2 (en) * 2003-02-17 2004-09-02 Cold Spring Harbor Laboratory Model for studying the role of genes in tumor resistance to chemotherapy
AU2003300359A1 (en) * 2003-05-08 2004-12-13 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005014618A2 (en) * 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
CA2539716A1 (en) * 2003-09-22 2005-04-07 Xcyte Therapies, Inc. Compositions and methods to accelerate hematologic recovery
WO2005049085A1 (en) * 2003-11-18 2005-06-02 Valeocyte Therapies Llc Use of soluble complexes to facilitate cell activation
WO2005075515A2 (en) * 2004-02-06 2005-08-18 Unilever N.V. Immunoglobulins and method for their modification
EP2479277B1 (en) 2004-07-22 2015-09-02 Five Prime Therapeutics, Inc. Use of MGD-CSF in a method of treatment of Alzheimer's disease.
FR2879605B1 (fr) * 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
US8137907B2 (en) * 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
US8444973B2 (en) * 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
KR101289537B1 (ko) * 2005-02-15 2013-07-31 듀크 유니버시티 항-cd19 항체 및 종양학에서 이의 용도
AU2006244445B2 (en) * 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
MX363423B (es) 2005-05-18 2019-03-22 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
EP2444424B1 (en) 2005-05-20 2018-08-08 Ablynx N.V. Improved nanobodies tm for the treatment of aggregation-mediated disorders
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
US20070044164A1 (en) * 2005-05-31 2007-02-22 Cold Spring Harbor Laboratory Methods for producing microRNAs
JP2008546647A (ja) * 2005-06-08 2008-12-25 デューク ユニバーシティ 移植のための抗−cd19抗体治療
ES2539250T3 (es) 2005-07-25 2015-06-29 Emergent Product Development Seattle, Llc Reducción de células B mediante el uso de moléculas de unión específica a CD37 y de unión específica a CD20
SG172698A1 (en) 2006-06-12 2011-07-28 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function
MX2009002414A (es) * 2006-09-08 2009-05-20 Medimmune Llc Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
WO2012130874A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Bispecific anti-cxcr7 immunoglobulin single variable domains
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
CA2672965C (en) 2006-12-19 2018-02-06 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
WO2009068628A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Constructs comprising single variable domains and an fc portion derived from lge.
EP2947097A1 (en) 2008-04-07 2015-11-25 Ablynx N.V. Amino acid sequences directed against the Notch pathways and uses thereof
SI2132228T1 (sl) 2008-04-11 2011-10-28 Emergent Product Dev Seatle CD37 imunoterapevtik in kombinacija z njegovim bifunkcionalnim kemoterapevtikom
AU2009273251B2 (en) 2008-07-22 2014-12-18 Ablynx Nv Amino acid sequences directed against multitarget scavenger receptors and polypeptides
EA024877B1 (ru) 2008-10-02 2016-10-31 Эмерджент Продакт Дивелопмент Сиэтл, Ллс Связывающие множество мишеней белки, обладающие антагонистическими свойствами по отношению к cd86
CA2758191C (en) 2009-04-10 2015-06-30 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
RU2016103067A (ru) 2009-06-05 2018-11-20 Аблинкс Нв Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей
EP2499488A1 (en) * 2009-11-14 2012-09-19 Kuang-Yuh Chyu Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP3309176A1 (en) 2009-12-14 2018-04-18 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011098518A2 (en) 2010-02-11 2011-08-18 Ablynx Nv Delivery of immunoglobulin variable domains and constructs thereof
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
MX2012013490A (es) 2010-05-20 2013-01-29 Ablynx Nv Materiales biologicos relacionados con her3.
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
EP2638068B1 (en) 2010-11-08 2018-12-26 Novartis AG Cxcr2 binding polypeptides
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2012175740A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Immunoglobulin single variable domains directed against ige
WO2013036130A1 (en) 2011-09-09 2013-03-14 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
DK2747782T3 (en) 2011-09-23 2018-04-23 Ablynx Nv Long-term inhibition of interleukin-6-mediated signal transmission
WO2013048243A1 (en) * 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
CN106046161B (zh) 2011-09-30 2019-09-13 埃博灵克斯股份有限公司 与C-Met相关的生物物质
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
JP2015504895A (ja) 2012-01-13 2015-02-16 エーピーオー‐ティー ビー.ヴイ. 毒性部分を備える異常細胞拘束性免疫グロブリン
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
US20160075766A1 (en) 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
AU2015261536B2 (en) 2014-05-16 2020-05-07 Ablynx Nv Improved immunoglobulin variable domains
CA2914595C (en) * 2014-05-19 2022-12-13 F. Hoffmann-La Roche Ag Method for producing antibodies using ovine b-cells and uses thereof
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
SG11201609707WA (en) 2014-07-01 2017-01-27 Pfizer Bispecific heterodimeric diabodies and uses thereof
CA2963037A1 (en) 2014-10-10 2016-04-14 Ablynx N.V. Treatment of rsv infection
TR201909589T4 (tr) 2014-10-10 2019-07-22 Ablynx Nv Solunum hastalıklarının aerosol terapisinde kullanıma yönelik inhalasyon cihazı.
ES2772348T3 (es) 2014-12-19 2020-07-07 Ablynx Nv Dímeros de Nanobody con uniones cisteína
JP6929786B2 (ja) 2015-04-02 2021-09-01 アブリンクス エン.ヴェー. 強力な抗hiv活性を有する二重特異性cxcr4−cd4ポリペプチド
AU2016246426B2 (en) 2015-04-06 2020-11-12 Arcellx, Inc De novo binding domain containing polypeptides and uses thereof
CN107847559B (zh) 2015-05-13 2022-07-01 埃博灵克斯股份有限公司 基于cd3反应性的t细胞募集多肽
SI3294768T1 (sl) 2015-05-13 2019-11-29 Ablynx Nv Polipeptidi, ki rekrutirajo celice T, na osnovi reaktivnosti TCR alfa/beta
KR20180053322A (ko) 2015-09-21 2018-05-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
CA3003334A1 (en) * 2015-10-28 2017-05-04 Life Technologies As Selective expansion of different subpopulations of t cells by the alteration of cell surfacing signals and signal ratio
NO2768984T3 (xx) 2015-11-12 2018-06-09
EP3932945A1 (en) 2015-11-27 2022-01-05 Ablynx NV Polypeptides inhibiting cd40l
JP2019512544A (ja) * 2016-03-15 2019-05-16 ネックスジェニア インコーポレイテッド 細胞表面分子結合性の刺激応答性重合体組成物および方法
WO2017167714A1 (en) 2016-03-30 2017-10-05 F. Hoffmann-La Roche Ag B-cell cultivation method
AU2017259876A1 (en) 2016-05-02 2018-10-25 Ablynx Nv Treatment of RSV infection
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
KR20240076829A (ko) 2016-11-16 2024-05-30 아블린쓰 엔.브이. Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
CN108264561B (zh) * 2016-12-30 2021-09-10 惠和生物技术(上海)有限公司 一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用
WO2018122147A1 (en) 2017-01-02 2018-07-05 F. Hoffmann-La Roche Ag B-cell cultivation method
JP2020519261A (ja) 2017-05-11 2020-07-02 ブイアイビー ブイゼットダブリュVib Vzw 可変免疫グロブリンドメインのグリコシル化
WO2018210896A1 (en) 2017-05-19 2018-11-22 F. Hoffmann-La Roche Ag Method for the production of thymocyte supernatant
JP2020521804A (ja) 2017-06-02 2020-07-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Mmp13結合免疫グロブリン
TW202413408A (zh) 2017-06-02 2024-04-01 比利時商艾伯林克斯公司 結合聚集蛋白聚糖之免疫球蛋白
MX2019014397A (es) 2017-06-02 2020-02-10 Merck Patent Gmbh Polipeptidos que enlazan adamts5, mmp13 y agrecano.
CN111032695B (zh) 2017-06-02 2024-06-25 默克专利股份有限公司 结合adamts的免疫球蛋白
AU2018369639A1 (en) 2017-11-14 2020-04-23 Arcellx, Inc. D-domain containing polypeptides and uses thereof
JP7166342B2 (ja) 2017-11-30 2022-11-07 エフ.ホフマン-ラ ロシュ アーゲー B細胞培養法
CN112004826B (zh) 2018-02-05 2024-06-14 自由大学基金会 反向激动性抗us28抗体
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
CN111655296A (zh) 2018-02-26 2020-09-11 埃博灵克斯股份有限公司 编码肽接头的经改良核苷酸序列
WO2019226050A2 (en) 2018-05-24 2019-11-28 Wageningen Universiteit Novel viral anti-infective reagents
EP3636657A1 (en) 2018-10-08 2020-04-15 Ablynx N.V. Chromatography-free antibody purification method
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
WO2020130838A2 (en) 2018-12-21 2020-06-25 Qvq Holding B.V. Antibodies for preventing or treating candidiasis
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
WO2020204714A1 (en) 2019-04-02 2020-10-08 Immunetune B.V. Immune-stimulatory compositions and use thereof
WO2020245663A1 (en) 2019-06-01 2020-12-10 Institut Pasteur Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection
WO2021025556A1 (en) 2019-08-05 2021-02-11 Stichting Vu Identification and elimination of hcmv-infected cells
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
KR20230166150A (ko) 2020-08-19 2023-12-06 젠코어 인코포레이티드 항-cd28 조성물
WO2022129637A1 (en) 2020-12-18 2022-06-23 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
US20240228593A9 (en) 2021-02-19 2024-07-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
WO2022216157A1 (en) 2021-04-09 2022-10-13 Stichting Radboud Universiteit Off the shelf proximity biotinylation enzyme
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
EP4381094A1 (en) 2021-08-03 2024-06-12 Wageningen Universiteit Argonaute-based nucleic acid detection system
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
US20240075068A1 (en) 2022-07-15 2024-03-07 Gadeta B.V. Novel soluble gamma T-cell (or soluble delta T-cell) receptor chains (or soluble gammadelta T-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
WO2024017915A1 (en) 2022-07-18 2024-01-25 Ablynx N.V. Cx3cr1-binding compounds, uses thereof and related methods
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024096735A1 (en) 2022-10-31 2024-05-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
WO2024101989A1 (en) 2022-11-08 2024-05-16 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy
WO2024133301A1 (en) 2022-12-19 2024-06-27 Umc Utrecht Holding B.V. Btn2a1 binding peptide
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
GB8927230D0 (en) * 1989-12-01 1990-01-31 Unilever Plc Reagents
DK0511011T3 (da) * 1991-04-26 1997-03-10 Surface Active Ltd Nye antistoffer og fremgangsmåde til anvendelse heraf
EP0584421A1 (en) * 1992-08-21 1994-03-02 Cécile Casterman Immunoglobulins devoid of light chains

Also Published As

Publication number Publication date
JP2003525016A (ja) 2003-08-26
ID26964A (id) 2001-02-22
AU3295299A (en) 1999-09-06
NO20004095D0 (no) 2000-08-16
IL137963A0 (en) 2001-10-31
NZ506453A (en) 2003-02-28
US20050261478A1 (en) 2005-11-24
HK1041210A1 (zh) 2002-07-05
US20020155604A1 (en) 2002-10-24
WO1999042077A2 (en) 1999-08-26
WO1999042077A3 (en) 2004-05-27
KR20010034512A (ko) 2001-04-25
EP1469883A2 (en) 2004-10-27
BR9907950A (pt) 2001-12-18
US20040253250A1 (en) 2004-12-16
NO20004095L (no) 2000-10-18
CN1316910A (zh) 2001-10-10

Similar Documents

Publication Publication Date Title
US20040253250A1 (en) Compositions and methods for regulating lymphocyte activation
JP4467188B2 (ja) 多重特異的結合分子とその使用
US5885573A (en) Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
Finney et al. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product
AU682325B2 (en) Methods for regulating the immune response using CTLA4-binding molecules and IL4-binding molecules
US20060002933A1 (en) Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
KR20220053587A (ko) 이형접합성 소실에 반응성인 세포 표면 수용체
WO1994028027A9 (en) Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
JP2002003399A (ja) 免疫疾患の治療のための可溶性ctla4タンパク質の使用
IL113343A (en) Ctla4/cd28 hybrid fusion proteins and compositions containing them
IL147448A (en) A monoclonal antibody of human origin against AILIM molecules that transmit an excitatory signal and pharmacological use of this antibody
WO1998058965A2 (en) B7-binding molecules for treating immune diseases
US20220249563A1 (en) Anti-dll3 chimeric antigen receptors and uses thereof
CA2157500C (en) Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
AU773844B2 (en) Compositions and methods for regulating lymphocyte activation
AU1872902A (en) Compositions and methods for regulating lymphocyte activation
EP1097210B1 (en) Immunological reagent specifically interacting with the extracellular domain of the human zeta chain
MXPA00008125A (en) Compositions and methods for regulating lymphocyte activation
CN117715935A (zh) 抗cd33抗体及其用途
CA2477192A1 (en) Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
JPH11332563A (ja) 抗体及びそれをコードする核酸
MXPA01000325A (en) Immunological reagent specifically interacting with the extracellular domain of the human zeta chain
MXPA95001794A (en) Ctla4 molecules and il-4 link molecules and uses of mis

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued